Clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn) for IgG-mediated autoimmune diseases
Clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn) for IgG-mediated autoimmune diseases. Its lead candidate, SYNT001, is a humanized monoclonal antibody designed to inhibit FcRn-IgG binding and reduce pathogenic IgG. Alexion agreed to acquire the company in 2018.